Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML). This updated analysis of the BELA trial assessed the safety profile and management of toxicities of bosutinib versus imat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Hematol
Autors principals: Gambacorti-Passerini, Carlo, Cortes, Jorge E, Lipton, Jeff H, Dmoszynska, Anna, Wong, Raymond S, Rossiev, Victor, Pavlov, Dmitri, Gogat Marchant, Karin, Duvillié, Ladan, Khattry, Navin, Kantarjian, Hagop M, Brümmendorf, Tim H
Format: Artigo
Idioma:Inglês
Publicat: BlackWell Publishing Ltd 2014
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4305212/
https://ncbi.nlm.nih.gov/pubmed/24944159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23788
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars